Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics

Next Previous
Drug Profile

Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics

Alternative Names: AMRS-001; CDNF - MANF Therapeutics; Cerebral dopamine neurotrophic factor - MANF Therapeutics; Conserved dopaminergic neurotrophic factor; MANF-based therapeutics - MANF Therapeutics; Mesencephalic astrocyte-derived neurotrophic factor; Recombinant MANF - MANF Therapeutics; rhMANF - MANF Therapeutics

Latest Information Update: 28 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amarantus Therapeutics; University of Miami
  • Developer Amarantus Bioscience Holdings; Generex Biotechnology Corporation; MANF Therapeutics
  • Class Antidementias; Antihyperglycaemics; Antiparkinsonians; Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Retinal artery occlusion
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Alzheimer's disease; Amyotrophic lateral sclerosis; Brain injuries; Diabetes mellitus; Glaucoma; Ischaemic heart disorders; Macular degeneration; Parkinson's disease; Retinal artery occlusion; Retinal vein occlusion; Retinitis pigmentosa; Spinocerebellar degeneration; Stroke

Most Recent Events

  • 28 Jul 2022 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
  • 28 Jun 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral)
  • 28 Jun 2020 No recent reports of development identified for preclinical development in Glaucoma in USA (Intravitreous, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top